Complex methodology for rational design of Apremilast-benzoic acid co-crystallization process.
Apremilast
Benzoic acid
Co-crystal
Crystallization
Solubility
Ternary phase diagram
Thermodynamic model
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
06
06
2019
revised:
17
08
2019
accepted:
20
08
2019
pubmed:
30
8
2019
medline:
12
2
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
A new co-crystal of pharmaceutical active ingredient Apremilast was successfully designed in this work. The discovered co-crystal with benzoic acid significantly improves key properties like the dissolution and stability of an otherwise poorly soluble Apremilast. A crystallization process was developed, which includes efficient solvent selection and ternary phase diagram construction to minimize risks during scale up. To increase efficiency, we propose that both steps be combined into a single methodology based on solubility data. A suitable solvent for the co-crystallization process was selected and ternary phase diagrams were constructed using three different modifications of thermodynamic model of solid-liquid equilibria. Based on the obtained information, the co-crystallization process was scaled-up to 100 mL. This provides a feasible process to produce larger amounts of this promising pharmaceutical solid form of Apremilast necessary for further drug development.
Identifiants
pubmed: 31465834
pii: S0378-5173(19)30684-2
doi: 10.1016/j.ijpharm.2019.118639
pii:
doi:
Substances chimiques
Solvents
0
Thalidomide
4Z8R6ORS6L
Benzoic Acid
8SKN0B0MIM
apremilast
UP7QBP99PN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118639Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.